Phosphopeptide pY816 Uncouples TrkB from PLCγ1 for Epilepsy Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for epilepsy, particularly temporal lobe epilepsy, are inadequate as they are often resistant to anticonvulsant drugs and lack preventive or disease-modifying therapies, with existing therapies only providing symptomatic relief and no effective cure, and there is a need for novel therapeutic approaches targeting the underlying mechanisms of limbic epileptogenesis.
Innovation Solution
Development of a therapeutic strategy that involves inhibiting the TrkB-mediated activation of PLCγ1 by using a phosphopeptide, such as pY816, to uncouple TrkB from PLCγ1, thereby disrupting the physical interaction and reducing seizure activity and anxiety-like behaviors in animal models.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional anticonvulsant drugs are used for treating epilepsy, then symptomatic relief is provided, but the treatment is resistant and lacks preventive or disease-modifying effects
Solution Approach 1:
The patent extracts and targets the specific TrkB-PLCγ1 signaling pathway that drives epileptogenesis, separating this pathological mechanism from the complex network of neuronal signaling. By using a phosphopeptide inhibitor that specifically blocks TrkB-mediated PLCγ1 activation, the treatment addresses the root cause of epilepsy development rather than merely suppressing symptoms, thereby providing both therapeutic and preventive effects against drug-resistant temporal lobe epilepsy
Solution Approach 2:
The patent changes the parameter of molecular interaction by introducing a phosphopeptide inhibitor that mimics the phosphorylated tyrosine residue (pY816) of TrkB receptor. This parameter change at the molecular level allows selective binding to PLCγ1 and blocks the pathological signaling cascade, transforming the treatment mechanism from broad-spectrum symptomatic suppression to targeted pathway inhibition with disease-modifying potential
2Object-affected harmful factors
If TrkB signaling is inhibited to prevent epileptogenesis, then seizure prevention is achieved, but normal neurotrophic functions may be affected
Solution Approach 1:
The patent applies local quality by designing a phosphopeptide inhibitor with specific molecular recognition properties that target only the TrkB-PLCγ1 interaction interface. The phosphopeptide contains a specific sequence (pY816) that mimics the phosphorylated tyrosine residue, enabling selective binding to PLCγ1's SH2 domain. This localized specificity ensures that only the pathological epileptogenic signaling is blocked while other TrkB-mediated neurotrophic functions remain intact
Solution Approach 2:
The phosphopeptide acts as an intermediary molecule that binds between TrkB receptor and PLCγ1 enzyme, physically blocking their interaction without inhibiting TrkB's other functions. This intermediary approach allows selective disruption of the harmful signaling pathway while preserving beneficial neurotrophic signaling through other pathways, thereby reducing side effects
Data Source
AI summary
The invention provides pharmaceutical compositions and methods of use thereof for preventing or ameliorating disorders of the nervous system. More specifically, the invention provides pharmaceutical compositions, including phosphopeptides that when administered disrupt the physical interaction of TrkB with its signaling effector, phospholipase Cγ1 (PLCγ1). The invention further provides method of treatment comprising administering phosphopeptides that uncouple TrkB from PLCγ1 in order to prevent and/or ameliorate nervous system disorders such as epilepsy, anxiety, and seizures.